Figure legends lists
Figure 1. Patient recruitment flowchart
Figure 2. Kaplan‐Meier curve showing progression‐free survival
for the whole cohort of patients treated with programmed cell death
protein‐1 (PD‐1)‐targeted immunotherapy
Figure 3. Kaplan‐Meier curves showing progression‐free survival
for Toripalimab‐, Camrelizumab and Sintilimab‐treated patients
Figure 4. Kaplan‐Meier curve showing time to progression for
the whole cohort of patients treated with programmed cell death
protein‐1 (PD‐1)‐targeted immunotherapy
Figure 5. Kaplan‐Meier curves showing time to progression for
Toripalimab‐, Camrelizumab and Sintilimab‐treated patients
Figure 6. Kaplan‐Meier curve showing overall survival for the
whole cohort of patients treated with programmed cell death protein‐1
(PD‐1)‐targeted immunotherapy
Figure 7. Kaplan‐Meier curves showing overall survival for
Toripalimab‐, Camrelizumab and Sintilimab‐treated patients